Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...
Banner Image
Mobile banner image

Pfizer Oncology
Development

Overview - by Phase

Geo Regions

View studies/programs by

Cancer Type Phase
Cancer types
Phases
Study status

Phase 1

Presentation Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Atirmociclib (PF-07220060)

Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Atirmociclib (PF-07220060)

PROTAC® Estrogen Receptor Degrader
CDK4 Inhibitor
Phase 1
Presentation CDK2 Inhibitor + Atirmociclib (PF-07220060)

CDK2 Inhibitor + Atirmociclib (PF-07220060)

PF-07104091
CDK4 Inhibitor
Phase 1
Presentation Atirmociclib (PF-07220060)

Atirmociclib (PF-07220060)

CDK4 Inhibitor
Phase 1
Presentation KAT6 Inhibitor + Atirmociclib (PF-07220060)

KAT6 Inhibitor + Atirmociclib (PF-07220060)

PF-07248144
CDK4 Inhibitor
Phase 1
Presentation Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

PF-08046052 | SGN-EGFRd2
Phase 1
Presentation BRAFi

BRAFi

PF-07799933 | ARRY-440
Phase 1
rotating image for CD228-directed Antibody-Anticalin® Bispecific Protein

CD228 and 4-1BB-directed Antibody-Anticalin® Bispecific Protein

PF-08046049 | SGN-BB228 
Phase 1
Presentation CD30-directed Antibody-Glucuronide with TOP1 Inhibitor Payload

CD30-directed Antibody-Glucuronide with TOP1 Inhibitor Payload

PF-08046044 | SGN-35C
Phase 1
rotating gif of SGN-35T

CD30-directed Antibody-Tripeptide MMAE Conjugate

PF-08046045 | SGN-35T
Phase 1
Presentation CDK2 Inhibitor

CDK2 Inhibitor

PF-07104091
Phase 1
Presentation CEACAM5-directed Antibody Drug Conjugate

CEACAM5-directed Antibody Drug Conjugate

PF-08046050 | SGN-CEACAM5C
Phase 1
rotating image for Disitamab vedotin

Disitamab vedotin

HER2-directed Antibody Drug Conjugate
Phase 1
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Phase 1
image representing elranatamab

Elranatamab + Maplirpacept (TTI-622 | PF-07901801)

BCMA-CD3 Bispecific Antibody
SIRPα-IgG4 Fusion Protein
Phase 1
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Phase 1
orange rotating molecule

Felmetatug vedotin (PF-08046048 | SGN-B7H4V)

B7-H4-directed Antibody Drug Conjugate
Phase 1
Presentation IL-12 Mutein

IL-12 Mutein

PF-07921585
Phase 1
Presentation Integrin alpha-V/beta-8 Antagonist

Integrin alpha-V/beta-8 Antagonist

PF-06940434 
Phase 1
Presentation KAT6 Inhibitor

KAT6 Inhibitor

PF-07248144
Phase 1
Presentation LILRB1/2 Bispecific IgG1 Antibody

LILRB1/2 Bispecific IgG1 Antibody

PF-07826390
Phase 1
image representing maplirpacept

Maplirpacept (TTI-622 | PF-07901801)

SIRPα-IgG4 Fusion Protein
Phase 1
Presentation MEK Brain Penetrant Inhibitor

MEK Brain Penetrant Inhibitor

PF-07799544 | ARRY-134
Phase 1
Presentation Mesothelin-Targeted Antibody Drug Conjugate

Mesothelin-Targeted Antibody Drug Conjugate

PF-08052666 | SGN-MesoC2
Phase 1
Presentation Mevrometostat (PF-06821497)

Mevrometostat (PF-06821497)

EZH2 Inhibitor
Phase 1
rotating gif for Non-Fucosylated CD70-directed Antibody

Non-Fucosylated CD70-directed Antibody

PF-08046040 | SEA-CD70
Phase 1
Presentation Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Palbociclib

Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Palbociclib

PROTAC® Estrogen Receptor Degrader
CDK4/6 Inhibitor
Phase 1
rotating gif of PF-08046054, SGN-PDL1V

PD-L1-directed Antibody Drug Conjugate

PF-08046054 | SGN-PDL1V
Phase 1
green molecule rotates

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate

SGN-B6A
Phase 1
Presentation STING Agonist

STING Agonist

PF-07820435
Phase 1
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
Phase 1
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Phase 1
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC® Estrogen Receptor Degrader

PROTAC® Estrogen Receptor Degrader
Phase 1

Phase 2

Presentation CDK2 Inhibitor + Atirmociclib (PF-07220060)

CDK2 Inhibitor + Atirmociclib (PF-07220060)

PF-07104091
CDK4 Inhibitor
Phase 2
Presentation Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Atirmociclib (PF-07220060)

Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Atirmociclib (PF-07220060)

PROTAC® Estrogen Receptor Degrader
CDK4 Inhibitor
Phase 2
Presentation Atirmociclib (PF-07220060)

Atirmociclib (PF-07220060)

CDK4 Inhibitor
Phase 2
Presentation Encorafenib + Binimetinib

Encorafenib + Binimetinib

BRAF Inhibitor
MEK Inhibitor
Phase 2
rotating image for Brentuximab vedotin

Brentuximab vedotin

CD30-directed Antibody Drug Conjugate
Phase 2
Presentation CDK2 Inhibitor

CDK2 Inhibitor

PF-07104091
Phase 2
rotating image for Disitamab vedotin

Disitamab vedotin

HER2-directed Antibody Drug Conjugate
Phase 2
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Phase 2
Presentation Encorafenib

Encorafenib

BRAF Inhibitor
Phase 2
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Phase 2
image representing maplirpacept

Maplirpacept (TTI-622 | PF-07901801)

SIRPα-IgG4 Fusion Protein
Phase 2
Presentation Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Palbociclib

Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Palbociclib

PROTAC® Estrogen Receptor Degrader
CDK4/6 Inhibitor
Phase 2
Image representing palbociclib

Palbociclib

CDK4/6 Inhibitor
Phase 2
Presentation Sasanlimab

Sasanlimab

Anti-PD-1 Monoclonal Antibody (mAb)
Phase 2
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
Phase 2
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Phase 2
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC® Estrogen Receptor Degrader

PROTAC® Estrogen Receptor Degrader
Phase 2

Phase 3

Presentation Atirmociclib (PF-07220060)

Atirmociclib (PF-07220060)

CDK4 Inhibitor
Phase 3
Presentation Encorafenib + Binimetinib

Encorafenib + Binimetinib

BRAF Inhibitor
MEK Inhibitor
Phase 3
rotating image for Brentuximab vedotin

Brentuximab vedotin

CD30-directed Antibody Drug Conjugate
Phase 3
rotating image for Disitamab vedotin

Disitamab vedotin

HER2-directed Antibody Drug Conjugate
Phase 3
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Phase 3
Presentation Encorafenib

Encorafenib

BRAF Inhibitor
Phase 3
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Phase 3
Presentation Talazoparib + Enzalutamide

Talazoparib + Enzalutamide

PARP Inhibitor
Androgen Receptor Inhibitor
Phase 3
Presentation Mevrometostat (PF-06821497) + Enzalutamide

Mevrometostat (PF-06821497) + Enzalutamide

EZH2 Inhibitor
Androgen Receptor Inhibitor
Phase 3
Presentation Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Palbociclib

Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Palbociclib

PROTAC® Estrogen Receptor Degrader
CDK4/6 Inhibitor
Phase 3
Image representing palbociclib

Palbociclib

CDK4/6 Inhibitor
Phase 3
Presentation Sasanlimab

Sasanlimab

Anti-PD-1 Monoclonal Antibody (mAb)
Phase 3
green molecule rotates

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate

SGN-B6A
Phase 3
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
Phase 3
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Phase 3
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC® Estrogen Receptor Degrader

PROTAC® Estrogen Receptor Degrader
Phase 3

Efficacy and safety of these products, for the uses identified within, are currently under investigation. Regulatory approval of any of these products or uses is dependent on the completion of the study programs and review by regulatory authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of February 4, 2025.

*Vepdegestrant is being co-developed with Arvinas.

Anticalin® is a registered US trademark of Pieris Pharmaceuticals Gmbh.